<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00973882</url>
  </required_header>
  <id_info>
    <org_study_id>CARBETOP</org_study_id>
    <secondary_id>ET2005-005</secondary_id>
    <nct_id>NCT00973882</nct_id>
  </id_info>
  <brief_title>Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers</brief_title>
  <official_title>Phase II Multicenter Study Evaluating the Efficacy of Carboplatin-Etoposide Combination in Hormone-resistant Prostate Cancers With Neuroendocrine Differentiation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to assess the efficacy and toxicity of a chemotherapy regimen
      combining carboplatin and etoposide in patients with metastatic hormone-resistant prostate
      cancer and neuro-endocrine differentiation. Eligible patients are treated with the
      combination of carboplatin AUC4 on day 1 and etoposide 100 mg/m2 on day 1, day 2 and day 3
      repeated every 3 weeks for a maximum of 6 cycles. Efficacy endpoints include Prostate
      Specific Antigen (PSA) and neuro-endocrine marker response (defined as a 50% or greater
      decrease from baseline serum values), objective response rate (according to RECIST criteria),
      and toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuro-endocrine differentiation is observed in the evolution of hormone-resistant prostate
      cancer. The aim of our study is to assess the efficacy and toxicity of a chemotherapy regimen
      combining carboplatin and etoposide in patients with metastatic hormone-resistant prostate
      cancer and neuro-endocrine differentiation. To be eligible, patients must have either
      circulating neuro-endocrine markers (Chromogranin A: CgA, Neuron Specific Enolase: NSE)and/or
      visceral metastases. Eligible patients are treated with the combination of carboplatin AUC4
      administered on day 1 and etoposide 100 mg/m2 given on day 1, day 2 and day 3 and repeated
      every 3 weeks for a maximum of 6 cycles. The primary objective of the study is to assess
      objective response to the carboplatin - etoposide combination (according to RECIST criteria
      for lesions and defined as a 50% or greater decrease from baseline serum values for PSA and
      neuro-endocrine markers). Secondary objectives include evaluation of toxicity, duration of
      response, progression-free-survival and overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (clinical and/or biological): Clinical: objective response of target lesions according to RECIST criteria Biological: greater than 50% decrease of PSA, NSE and Chromogranin A levels</measure>
    <time_frame>Every 6 weeks during treatment (6 cycles of carboplatin-etoposide) and 3 to 4 weeks after the end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (clinical and/or biological)</measure>
    <time_frame>Every three months until progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Every 3 weeks during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival and overall survival</measure>
    <time_frame>Every three months until progression</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Carboplatin-Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles</description>
    <arm_group_label>Carboplatin-Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles</description>
    <arm_group_label>Carboplatin-Etoposide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological evidence of prostate adenocarcinoma

          -  Metastatic disease, either measurable (lymph nodes, hepatic lesion, pulmonary lesions
             with longest diameter &gt; or = 1 cm on spiral scan), or non measurable (bone metastasis)

          -  Patients must:

               -  Have received hormonal therapy via surgical or chemical castration (LH-RH
                  agonist) with or without anti-androgens. Anti-androgen withdrawal is recommended
                  before inclusion, with an off-treatment period of at least 4 weeks. LH-RH agonist
                  treatment must be continued.

               -  Have a relapse or disease refractory to hormonal treatment (defined by a
                  testosterone level &lt; 0.5 Âµg/ml)

               -  Have neuroendocrine progression defined, whatever the PSA level, as:

                    -  NSE and/or Chromogranin A &gt; 1.5 x upper limit of normal (ULN) with or
                       without visceral metastases (liver, lung, lymph node)

                    -  No increase of NSE or Chromogranin A, but visceral metastases (either
                       hepatic, pleuro-pulmonary, or nodal) with cytological or histological
                       confirmation of the presence of an undifferentiated or neuro-endocrine
                       component of prostatic origin

          -  Prior treatment by radiotherapy is allowed but radiation therapy must have been
             completed for at least 4 weeks before inclusion and irradiated areas must not
             represent more than 25% of marrow reserves

          -  Prior treatment by estramustine is allowed but must have been stopped at least 4 weeks
             before inclusion

          -  Age&gt; or = 18 years

          -  Life expectancy&gt; or = 3 months

          -  Karnofsky index&gt; or = 50%

          -  Adequate haematological function: neutrophils&gt; or = 1.5 G/l, platelets&gt; or = 100 G/l,
             haemoglobin&gt; or = 8 g/dl. Use of erythropoietin is allowed.

          -  Adequate liver function: bilirubin level within the institution's normal range, AST
             and ALT&lt; or = 1.5 ULN

          -  Adequate renal function: creatinine clearance&gt; or = 40 ml/min (Gault and Cockroft
             method)

          -  Signed written informed consent.

        Exclusion Criteria:

          -  Patients having no&gt; 1.5 x ULN increase of at least one neuro-endocrine marker (NSE or
             chromogranin A) and no cytological or histological (undifferentiated or
             neuro-endocrine type) evidence of visceral metastasis (hepatic, pleuro-pulmonary, or
             nodal)

          -  History of other malignancies, other than curatively treated basal cell skin carcinoma
             or any other curatively treated cancer with no sign of recurrence within 5 years

          -  Symptomatically uncontrolled brain metastasis

          -  Interstitial radiation therapy (using strontium or samarium) within the previous 3
             months

          -  Prior treatment with platinum salts or etoposide. Other chemotherapy regimens are
             allowed provided that the last dose has been administered&gt; or = 4 weeks prior to
             inclusion.

          -  Concomitant treatment with other anti-cancer drugs, except corticoid or LH-RH agonist
             injections

          -  Peripheral neuropathy&gt; or = 2 (NCI-CTCAE)

          -  Uncontrolled progressive thrombo-embolic disease

          -  Uncontrolled infection

          -  Medical history of acute myocardial infection or uncontrolled angina pectoris, or
             hypertension or uncontrolled arrythmia

          -  Inclusion in another clinical trial

          -  Impaired follow-up for social, geographical, familial or psychological reasons

          -  Any other unstable disease.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>FLECHON Aude, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre FranÃ§ois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Henri Mondor</name>
      <address>
        <city>CrÃ©teil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges FranÃ§ois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier DÃ©partemental Les Oudairies</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation HÃ´pital Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital EuropÃ©en Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>SURESNES Cedex</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>AumÃ¼ller G, Leonhardt M, Janssen M, Konrad L, Bjartell A, Abrahamsson PA. Neurogenic origin of human prostate endocrine cells. Urology. 1999 May;53(5):1041-8.</citation>
    <PMID>10223503</PMID>
  </reference>
  <reference>
    <citation>Bonkhoff H, Stein U, Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol. 1995 Feb;26(2):167-70.</citation>
    <PMID>7532147</PMID>
  </reference>
  <reference>
    <citation>Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, van Krimpen H, SchrÃ¶der FH, van der Kwast TH. Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry. 1993 Nov;100(5):393-8.</citation>
    <PMID>8307781</PMID>
  </reference>
  <reference>
    <citation>Hansson J, Abrahamsson PA. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol. 2001;12 Suppl 2:S145-52. Review.</citation>
    <PMID>11762343</PMID>
  </reference>
  <reference>
    <citation>Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate. 1999 May;39(2):135-48. Review.</citation>
    <PMID>10221570</PMID>
  </reference>
  <reference>
    <citation>Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol. 1992 Mar;147(3 Pt 2):804-7.</citation>
    <PMID>1311395</PMID>
  </reference>
  <reference>
    <citation>Kreis W. Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer. Cancer Invest. 1995;13(3):296-312. Review.</citation>
    <PMID>7743383</PMID>
  </reference>
  <reference>
    <citation>Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996 Jun;14(6):1756-64.</citation>
    <PMID>8656243</PMID>
  </reference>
  <reference>
    <citation>Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol. 1994 Apr;12(4):689-94.</citation>
    <PMID>7512127</PMID>
  </reference>
  <reference>
    <citation>Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748-56.</citation>
    <PMID>2681557</PMID>
  </reference>
  <reference>
    <citation>Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, RochÃ© H, Houin G, Bugat R. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995 Apr 19;87(8):573-80.</citation>
    <PMID>7752255</PMID>
  </reference>
  <reference>
    <citation>Maksymiuk AW, Jett JR, Earle JD, Su JQ, Diegert FA, Mailliard JA, Kardinal CG, Krook JE, Veeder MH, Wiesenfeld M, et al. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol. 1994 Jan;12(1):70-6.</citation>
    <PMID>8270988</PMID>
  </reference>
  <reference>
    <citation>Loehrer PJ Sr, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, Einhorn LH. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol. 1995 Oct;13(10):2594-9.</citation>
    <PMID>7595712</PMID>
  </reference>
  <reference>
    <citation>Miller AA, Herndon JE 2nd, Hollis DR, Ellerton J, Langleben A, Richards F 2nd, Green MR. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol. 1995 Aug;13(8):1871-9.</citation>
    <PMID>7636529</PMID>
  </reference>
  <reference>
    <citation>Larive S, Bombaron P, Riou R, Fournel P, Perol M, Lena H, Dussopt C, Philip-Joet F, Touraine F, Lecaer H, Souquet PJ; Groupe Lyon-Saint Etienne d'Oncologie Thoracique. Carboplatin-etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial. Lung Cancer. 2002 Jan;35(1):1-7. Review.</citation>
    <PMID>11750705</PMID>
  </reference>
  <reference>
    <citation>Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999 Nov;17(11):3540-5.</citation>
    <PMID>10550152</PMID>
  </reference>
  <reference>
    <citation>Quoix E, Breton JL, Daniel C, Jacoulet P, Debieuvre D, Paillot N, Kessler R, Moreau L, CoÃ«tmeur D, LemariÃ© E, Milleron B. Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study. Ann Oncol. 2001 Jul;12(7):957-62.</citation>
    <PMID>11521802</PMID>
  </reference>
  <reference>
    <citation>Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002 Jul 15;20(14):3072-80.</citation>
    <PMID>12118020</PMID>
  </reference>
  <reference>
    <citation>Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1-10.</citation>
    <PMID>2702835</PMID>
  </reference>
  <reference>
    <citation>Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-81, 1958</citation>
  </reference>
  <results_reference>
    <citation>FlÃ©chon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, Joly F, Oudard S, Deplanque G, Zanetta S, Fargeot P, Priou F, Droz JP, Culine S. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol. 2011 Nov;22(11):2476-81. doi: 10.1093/annonc/mdr004. Epub 2011 Mar 24.</citation>
    <PMID>21436186</PMID>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <last_update_submitted>November 2, 2011</last_update_submitted>
  <last_update_submitted_qc>November 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hormone resistant prostate cancer</keyword>
  <keyword>Neuro-endocrine marker</keyword>
  <keyword>Carboplatin-Etoposide combination</keyword>
  <keyword>Neuro-endocrine differentiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

